Anand Bagaria, senior research analyst, Finquest explains to CNBC-TV18 that pharma major Wockhardt has posted a strong run in terms of a stock performance as well as fundamentals and gained over 250% from the start of the year.
In an interview to CNBC-TV18, Anand Bagaria of Finquest Securities, said the brokerage firm has a one-year target of Rs 600 on Wockhardt.